Company profile
Isodiol International Inc.
OTC: ISOLF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, BCReports USD
#576 of 1,422 Healthcare companies by revenue58th-percentile growth
EA Score
——FH —DQ —GM —SS 32
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, Piotroski F · ↓ Altman-Z, return on equity
Methodology →Revenue TTM
$11.9k
Rev growth YoY (TTM)
-17.7%
Net income (FY)
-$90.3M
Employees
—
as of 2026-08-30
Market cap
$4.9k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$16.7M$16.7M2018
Net income-$90.3M-$90.3M2018
Operating income-$29.2M-$29.2M2018
Total assets$17.7M$17.7M2018
Liabilities$12.5M$12.5M2018
Equity$5.2M$5.2M2018
Revenue trend
FY2015 – FY2018 · USD
FY15
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Isodiol International Inc.’s revenue?
Isodiol International Inc. booked $16.7M in FY2018 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a -542.1% net margin.
Peers · Healthcare
Choom Holdings Inc.——Veru Inc.49DPelthos Therapeutics Inc.37DInspire Veterinary Partners, Inc.——Seer, Inc.50DStem Holdings, Inc.——Key facts
CEOMarcos Agramont
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, BC
ExchangeOTC: ISOLF
Employees—
IPO date2014-11-20
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.